Sign In   Register

Cannabis and Hemp Industry Investment News

Cannabis Industry Press Releases and News Articles from the best investment journalist in the industry. Stay updated on all cannabis investment news from every online source, on MjInvest.com

CannPal Animal Therapeutics major shareholder increases stake

An Australian fund manager has increased its stake to 19.61% in the company. A number of board and management personnel have been buying shares recent...

CannPal Animal Therapeutics managing director buys more shares on-market

What are you searching for? viewCannPal Animal Therapeutics Ltd A number of board members have purchased shares in the company in 2019 to date. The sh...

CannPal Animal Therapeutics files new patent application as industry-leading research is recognised

The company’s research results into cannabinoid treatments for animals have been presented at a leading veterinary conference. Lead drug candidate CPA...

CannPal Animal Therapeutics R&D research to be published in leading veterinary journal

The company will present findings of study into cannabinoid treatment for companion animals at AVA Innovation Symposium next month. The company is foc...

CannPal Animal Therapeutics director buys 100,000 shares on-market

What are you searching for? viewCannPal Animal Therapeutics Ltd This follows chairman Geoff Starr’s on-market share purchases last month. The company ...

CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

This is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well u...

CannPal Animal Therapeutics receives approvals for two clinical studies

CPAT-01 is CP1’s lead pharmaceutical product and is derived from cannabinoids. CPAT-01’s market is estimated to be worth US$1 billion globally () has ...

CannPal Animal Therapeutics chairman buys company shares

What are you searching for? viewCannPal Animal Therapeutics Ltd 80,000 shares at a cost of $10,193 represents a 12.7 cents per share average cost pric...

CannPal Animal Therapeutics well capitalised as it moves towards commercialisation phase

() intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study o...

CannPal Animal Therapeutics director shows faith in company through on-market purchase

Non-executive director Rob Clifford now holds more than 480,000 shares in an indirect interest. The cannabis-derived pain control drug candidate CPAT-...

CannPal Animal Therapeutics concludes successful phase 1B cannabinoid study in dogs

CannPal’s aim is to be one of the first companies to provide veterinarians with GMP-produced and regulatory approved cannabinoid-derived therapeutics ...

CannPal Animal Therapeutics director acquires further shares on-market

Non-executive director Max Johnston now holds 200,000 shares in an indirect interest. The cannabis-derived pain control drug candidate CPAT-01 is targ...

CannPal Animal Therapeutics caps off busy September quarter

The company had a healthy cash balance of $4.72 million at the end of the quarter. The company is researching the benefits of medical cannabis for dog...

Cannpal Animal Therapeutics director shows confidence in company’s cannabis-derived animal medications

Non-executive director Max Johnston has acquired shares on-market valued at more than $9,000. The company is developing cannabis-based pharmaceuticals...

CannPal Animal Therapeutics’ sponsor fee for lead animal drug candidate waived by US FDA

CannPal plans to take the results from its recently commenced phase 1A and B studies to file an Investigational New Animal Drug application with the F...

CannPal Animal Therapeutics commences dog pain control study

The company will move onto phase II studies after this phase is complete. Shares have rallied to 20 cents recently, up from last month's low of 16.5 c...

CannPal Animal Therapeutics teams up with University of Melbourne

A cooperative relationship in the field of veterinary science will be established. The aim is to complete a pilot study targeting epilepsy in dogs in ...

CannPal Animal Therapeutics receives approval to advance clinical studies

Results from the phase Ib study are expected during this September quarter. The cannabis-derived pain control drug candidate CPAT-01 is targeting cats...

CannPal Animal Therapeutics positioned in a growing animal health market

The company's lead drug candidate is a cannabis-derived canine pain medication. The company listed on the ASX in October 2017 via IPO () is leveraged ...


CannPal Animal Therapeutics to research a cannabis-derived pain treatment for cats

The company has entered into a research services agreement Eurofins Animal Health Pty Ltd. The collaboration will seek to expand the development progr...


MjInvest.com